In The News

EPI Health and MC2 Therapeutics Announce Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) now covered on Express Scripts National Preferred Formulary

 NEWS PROVIDED BY  EPI Health, LLC  November 9, 2021, 08:00 ET  ---  Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older.  CHARLESTON, SC, USA and...

read more

Highly Significant Head to Head Data for Wynzora® Cream (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%) for the Treatment of Plaque Psoriasis Accepted to Maui Derm Summer Meeting

PRESS RELEASE for distribution July 6, 2021 Two posters featuring highly significant head to head data for Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) vs Taclonex® Topical Suspension were shown at the Maui Derm NPPA Summer meeting...

read more